Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
1999-06-17
2004-07-06
Chan, Christina (Department: 1644)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C530S324000, C530S356000, C514S012200
Reexamination Certificate
active
06759047
ABSTRACT:
BACKGROUND OF THE INVENTION
Vascular basement membranes are composed of macromolecules such as collagen, laminin, heparan sulfate proteoglycans, fibronectin and entactin (Timpl, R., 1996, Curr Opin Cell Biol 8:618-24). Functionally, collagen promotes cell adhesion, migration, differentiation and growth (Paulsson, M., 1992, Crit. Rev. Biochem. Mol. Biol. 27:93-127), and via these functions is presumed to play a crucial role in endothelial cell proliferation and behavior during angiogenesis, which is the process of formation of new blood vessels from pre-existing ones (Madri, J. A. et al., 1986, J. Histochem. Cytochem. 34:85-91; Folkman, J., 1972, Ann. Surg. 175:409-16). Angiogenesis is a complex process, and requires sprouting and migration of endothelial cells, proliferation of those cells, and their differentiation into tube-like structures and the production of a basement membrane matrix around the developing blood vessel. Additionally angiogenesis is a process critical for normal physiological events such as wound repair and endometrium remodeling (Folkman, J. et al., 1995, J. Biol. Chem. 267:10931-34). It is now well documented that angiogenesis is required for metastasis and growth of solid tumors beyond a few mm in size (Folkman, J., 1972, Ann. Surg. 175:409-16; Folkman, J., 1995, Nat. Med. 1:27-31). Several studies have shown that inhibitors of collagen metabolism have anti-angiogenic properties, supporting the notion that basement membrane collagen synthesis and deposition is crucial for blood vessel formation and survival (Maragoudakis, M. E. et al., 1994, Kidney Int. 43:147-50; Haralabopoulos, G. C. et al., 1994, Lab. Invest. 71:575-82). However, the precise role of collagen in basement membrane organization and angiogenesis is still not well understood.
SUMMARY OF THE INVENTION
The present invention relates to proteins comprising the NC1 domain of an alpha chain of Type IV collagen having anti-angiogenic properties. In particular, the present invention relates to the novel proteins Arresten, Canstatin and Tumstatin, and to biologically active (e.g., anti-angiogenic) fragments, mutants, analogs, homologs and derivatives thereof, as well as multimers (e.g., dimers) and fusion proteins (also referred to herein as chimeric proteins) thereof. These proteins all comprise the C-terminal fragment of the NC1 (non-collagenous 1) domain of Type IV collagen. More specifically, Arresten, Canstatin and Tumstatin are each a C-terminal fragment of the NC1 domain of the &agr;1 chain, &agr;2 chain and &agr;3 chain, respectively, of Type IV collagen. In particular, Arresten, Canstatin and Tumstatin are monomeric proteins. All three arrest tumor growth in vivo, and also inhibit the formation of capillaries in several in vitro models, including the endothelial tube assay.
The present invention encompasses isolated and recombinantly-produced Arresten, also referred to herein as “Arrestin,” which comprises the NC1 domain of the &agr;1 chain of Type IV collagen, having anti-angiogenic activity, anti-angiogenic fragments of the isolated Arresten, multimers of the isolated Arresten and anti-angiogenic fragments, and polynucleotides encoding those anti-angiogenic proteins. Also encompassed are compositions comprising isolated Arresten, its anti-angiogenic fragments, or both, as biologically active components. In another embodiment, the invention features a method of treating a proliferative disease such as cancer, in a mammal where said disease is characterized by angiogenic activity, the method comprising administering to the mammal a composition containing anti-angiogenic Arresten or its fragments. The anti-angiogenic Arresten and its fragments can also be used to prevent cell migration or endothelial cell proliferation. Also featured are antibodies to the isolated anti-angiogenic Arresten and its fragments.
The present invention also encompasses isolated and recombinantly produced Canstatin, which comprises the NC1 domain of the &agr;2 chain of Type IV collagen, having anti-angiogenic activity, anti-angiogenic fragments of the isolated Canstatin, multimers of the isolated Canstatin and anti-angiogenic fragments, and polynucleotides encoding those anti-angiogenic proteins. Also encompassed are compositions comprising isolated Canstatin, its anti-angiogenic fragments, or both, as biologically active ingredients. In another embodiment, the invention features a method of treating a proliferative disease such as cancer, in a mammal, where said disease is characterized by angiogenic activity, the method comprising administering to the mammal a composition containing anti-angiogenic Canstatin or its fragments. The anti-angiogenic Canstatin and its fragments can also be used to prevent cell migration or endothelial cell proliferation. Also featured are antibodies to the isolated anti-angiogenic Canstatin and its fragments.
The invention likewise encompasses isolated and recombinantly-produced Tumstatin, comprising the NC1 domain of the &agr;3 chain of Type IV collagen, having anti-angiogenic activity, anti-angiogenic fragments of the isolated Tumstatin, multimers of the isolated Tumstatin and anti-angiogenic fragments, and polynucleotides encoding those anti-angiogenic proteins. Also encompassed are compositions comprising isolated Tumstatin, its anti-angiogenic fragments, or both, as biologically active ingredients. In another embodiment, the invention features a method of treating a proliferative disease such as cancer in a mammal, where said disease is characterized by angiogenic activity, the method comprising administering to the mammal a composition containing anti-angiogenic Tumstatin or its fragments. The anti-angiogenic Tumstatin and its fragments can also be used to prevent cell migration or endothelial cell proliferation. Also featured are antibodies to the isolated anti-angiogenic Tumstatin and its fragments.
REFERENCES:
patent: 5114840 (1992-05-01), Tryggvason et al.
patent: 5424408 (1995-06-01), Reeders et al.
patent: 5567609 (1996-10-01), Sarras, Jr. et al.
patent: 5593900 (1997-01-01), Tryggvason et al.
patent: 5691182 (1997-11-01), Sarras, Jr. et al.
patent: 5731192 (1998-03-01), Reeders et al.
patent: 5753230 (1998-05-01), Brooks et al.
patent: 5766591 (1998-06-01), Brooks et al.
patent: 5856184 (1999-01-01), Sarras, Jr. et al.
patent: 5973120 (1999-10-01), Reeders et al.
patent: 6007980 (1999-12-01), Reeders et al.
patent: 6017926 (2000-01-01), Askew et al.
patent: WO 89/03392 (1989-04-01), None
patent: WO 91/08755 (1991-06-01), None
patent: WO 91/09113 (1991-06-01), None
patent: WO 96/00582 (1996-01-01), None
patent: WO 97/06791 (1997-02-01), None
patent: WO 97/45137 (1997-12-01), None
patent: WO 99/02551 (1999-01-01), None
patent: WO 99/16465 (1999-04-01), None
patent: WO 99/49885 (1999-10-01), None
patent: WO 99/65940 (1999-12-01), None
patent: WO 00/11475 (2000-03-01), None
patent: WO 00/31248 (2000-06-01), None
patent: WO 00/59532 (2000-10-01), None
Battegay, E.J., Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects, J. Mol. Med. 73:333-346, 1995.*
Bergers et al., Effects of Angiogenesis Inhibitors on Multistage Carcinogenesis in Mice, Science 284:808-812, Apr., 1999.*
Attwood TK. Genomics. The Babel of bioinformatics. Science. 290(5491):471-473, 2000.*
Skolnick et al. From genes to protein structure and function: novel applications of computational approaches in the genomic era. Trends Biotechnol. 18(1):34-9, 2000.*
Ngo J.T, Marks J., Karplus M., Computational complexity, protein structure prediction, and the Levinthal paradox in The Protein Folding Problem, ch.14, pp. 435-508, Birkhauser, 1994.*
Tai-Ping et al., Trends in Pharm. Sci. 16(2):57-66, Feb. 1995.*
Skolnick et al., Trends in Biotech., 18(1):34-39, Jan. 2000.*
Wallace, R., Drug Discovery Today, 3(10):433-434, Oct., 1998.*
Sasaki et al., J. Mol. Biol. 301:1179-1190, 2000.*
Prestayko, A.W., et al., “Type IV collagen domains inhibit adhesion and migration of tumor cells and block angiogenesis,”Proceedings of the American Association for Cancer Research,39:45 (Mar. 1998).
Sado, Y.,
Beth Israel Deaconess Hospital Corp.
Chan Christina
Gyure Barbara A.
Haddad Maher M.
Palmer & Dodge LLP
LandOfFree
Anti-angiogenic proteins and methods of use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-angiogenic proteins and methods of use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-angiogenic proteins and methods of use thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3192571